Walenga J M, Petitou M, Samama M, Fareed J, Choay J
Loyola University Medical Center, Department of Pathology, Maywood, Illinois 60153.
Thromb Res. 1988 Dec 15;52(6):553-63. doi: 10.1016/0049-3848(88)90128-4.
Previous theoretical and experimental evidence led to the formulation of a specific pentasaccharide structure which represents the site in heparin for binding to antithrombin III. This pentasaccharide was subsequently synthesized. A pentasaccharide of the same structure but lacking only the sulfate group on the hydroxyl group of the middle glucosamine (position C-3) was also synthesized to test the structure - activity relationships. Previous biochemical studies showed the 3-O-desulfated pentasaccharide to have a low affinity binding to AT III and to be devoid of the high anti-factor Xa activity characteristic of the pentasaccharide. Our in vivo studies, in a venous stasis thrombosis model proved the 3-O-desulfated pentasaccharide, at equigravimetric dosages, to be devoid of the antithrombotic activity previously reported for the pentasaccharide. These studies confirm the fact that inhibition of factor Xa at a high level of activity produces an antithrombotic effect.
先前的理论和实验证据促使一种特定五糖结构的形成,该结构代表肝素中与抗凝血酶III结合的位点。随后合成了这种五糖。还合成了一种结构相同但仅在中间葡糖胺(C-3位)羟基上缺少硫酸基团的五糖,以测试结构-活性关系。先前的生化研究表明,3-O-去硫酸化五糖与抗凝血酶III的结合亲和力较低,并且缺乏五糖特有的高抗Xa因子活性。我们在静脉淤滞血栓形成模型中的体内研究证明,在等重量剂量下,3-O-去硫酸化五糖没有先前报道的五糖的抗血栓活性。这些研究证实了在高活性水平下抑制Xa因子会产生抗血栓作用这一事实。